❌

Normal view

Received — 8 April 2026 ⏭ Nature Medicine

Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial

✇Nature Medicine
By: Gerald F. Watts · Russell Scott · David Sullivan · John Baker · Peter Clifton · James Hamilton · Bruce Given · Stacey Melquist · Rong Zhou · Daniel Gaudet · Ira J. Goldberg · Joshua W. Knowles · Nicholas J. Leeper · Robert A. Hegele · Christie M. Ballantyne
7 April 2026 at 08:00

Nature Medicine, Published online: 07 April 2026; doi:10.1038/s41591-026-04307-8

In a phase 1 basket trial, the small interfering RNA zodasiran, targeting ANGPTL3, lowered triglycerides in patients with severe hypertriglyceridemia and lowered both triglycerides and low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia.

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

✇Nature Medicine
By: Francesca Gay · Wilfried Roeloffzen · Meletios A. Dimopoulos · Laura Rosiñol · Marjolein van der Klift · Roberto Mina · Albert Oriol · Eirini Katodritou · Ka Lung Wu · Paula Rodríguez Otero · Roman Hájek · Elisabetta Antonioli · Mark van Duin · Mattia D’Agostino · Joaquín Martínez-López · Elena M. van Leeuwen-Segarceanu · Elena Zamagni · Niels W. C. J. van de Donk · Katja C. Weisel · Luděk Pour · Jakub Radocha · Angelo Belotti · Fredrik Schjesvold · Joan Bladé · Hermann Einsele · Pieter Sonneveld · Mario Boccadoro · Annemiek Broijl
6 April 2026 at 08:00

Nature Medicine, Published online: 06 April 2026; doi:10.1038/s41591-026-04282-0

In the phase 3 EMN24 IsKia trial, transplant-eligible patients with newly diagnosed multiple myeloma who received isatuximab with carfilzomib, lenalidomide and dexamethasone pretransplant induction and post-transplant consolidation showed higher rates of measurable residual disease negativity after consolidation than patients who received carfilzomib, lenalidomide and dexamethasone.

An international mega-analysis of psychedelic drug effects on brain circuit function

✇Nature Medicine
By: Manesh Girn · Manoj K. Doss · Leor Roseman · Katrin H. Preller · Fernanda Palhano-Fontes · Lorenzo Pasquini · Frederick S. Barrett · Pablo Mallaroni · Natasha L. Mason · Christopher Timmermann · Drummond E. McCulloch · Patrick M. Fisher · Brian S. Winston · Flora Moujaes · Felix Muller · Matthias E. Liechti · Franz X. Vollenweider · Johannes G. Ramaekers · Kim Kuypers · Draulio B. Araujo · Olaf Sporns · Joshua Siegel · Nico Dosenbach · David J. Nutt · Robin L. Carhart-Harris · Emmanuel A. Stamatakis · Danilo Bzdok
6 April 2026 at 08:00

Nature Medicine, Published online: 06 April 2026; doi:10.1038/s41591-026-04287-9

Analysis of neuroimaging datasets across five major psychedelics revealed a shared brain signature and provides a comprehensive insight into how these drugs reorganize brain architecture.
Received — 4 April 2026 ⏭ Nature Medicine

Evidence of monkeypox virus clade IIb lineage A.2.2 in the Republic of the Congo and co-circulation of clade Ia, Ib and clade IIb

✇Nature Medicine
By: Felix Koukouikila-Koussounda · Claude Kwe Yinda · Pembe Issamou Mayangue · Dachel Aymard Eyenet Boussam · Reiche Golmard Elenga · Leadisaelle Hosanna Lenguiya · Ghislain Dzeret Indolo · Bani Reize Vishnou Ampiri · Lucette Nathalie Macosso · Igor Judicaël Louzolo · Isaac Samuel Onyakouang · Jordy Exaucé Lyelet Demboux · Jean Medar Kankou · Aristide Gilbert Nianga · Avelin F. Aghokeng · Vincent Jacobus Munster · Fabien Roch Niama
3 April 2026 at 08:00

Nature Medicine, Published online: 03 April 2026; doi:10.1038/s41591-026-04256-2

Whole-genome phylogenetic analyses have identified a case of monkeypox virus clade IIb lineage in the Republic of the Congo and co-circulation of three clade lineages, emphasizing the importance of improved surveillance given the risk of possible recombination events in the future.

The exposome of brain aging across 34 countries

✇Nature Medicine
By: Agustina Legaz · Sebastian Moguilner · Pablo Barttfeld · Jhosmary Cuadros Castro · Dante Sebastián Galván Rial · Joaquin Migeot · Francesca R. Farina · Raul Gonzalez-Gomez · Salomón Salazar-Londoño · Tiago de Souza Azzi · Sarael Alcauter · Lucia Amoruso · Renato Anghinah · May Bakr · María Isabel Behrens · Martin A. Bruno · Juan Felipe Cardona · Christopher Chen · Olivier Colliot · Nilton Custodio · Quentin d’Acremont · Stéphanie Debette · Patrycja Dzianok · Bahar Güntekin · Jordi Huguet · Cecilia Jarne · Marc Joliot · Elissaios Karageorgiou · Eman M. Khedr · Sheri-Michelle Koopowitz · Ewa Kublik · Jinkook Lee · Leon Aksman · Susanna Lopez · Paula Margaretic · Diana Matallana · Sophie Matis · Andreas Miltiadous · Gabriela Novotni · Patricio Orio · Mario A. Parra · Simone Reppermund · Elisa de Paula França Resende · Giovanni Abrahão Salum · Andrea Slachevsky · Ana Luisa Sosa Ortiz · Leonel Tadao Takada · An Qi Toh · Alexandros Tzallas · Wei Wen · Robert Whelan · Görsev Yener · Jonathan Adrián Zegarra Valdivia · Athanasia Alexoudi · Faheem Arshad · Ha
3 April 2026 at 08:00

Nature Medicine, Published online: 03 April 2026; doi:10.1038/s41591-026-04302-z

Exposome analyses across 34 countries showed that social exposures were associated with faster functional brain aging and physical exposures with faster structural brain aging.

Target product profiles for treatments to delay or prevent symptomatic Alzheimer’s disease

✇Nature Medicine
By: Jeffrey L. Cummings · Michael G. Agadjanyan · Maureen Barry · Lawrence Corey · Rachelle Doody · Suzanne Hendrix · Soeren Mattke · Niklas Mattsson-Carlgren · Eric McDade · Joseph P. Menetski · Richard C. Mohs · Katherine A. Partrick · Nikolai Petrovsky · Dennis J. Selkoe · Diego Silva · Reisa A. Sperling · Benjamin Tiede · George Vradenburg
3 April 2026 at 08:00

Nature Medicine, Published online: 03 April 2026; doi:10.1038/s41591-026-04305-w

To accelerate therapeutic development and equip stakeholders with clear benchmarks, the authors outline target product profiles for therapies designed to delay or prevent the onset of clinical symptoms of Alzheimer’s disease.

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial

✇Nature Medicine
By: Sebastian M. Meyhöfer · Bertrand Cariou · Cintia Cercato · Helen M. Colhoun · John Deanfield · Michelle T. Long · Ole Kleist Jeppesen · A. Michael Lincoff · Ildiko Lingvay · Jorge Plutzky · Philip N. Newsome · Stephen J. Nicholls · Maria Quiroga · Ferruccio Santini · Arun J. Sanyal · Steven E. Kahn · Donna H. Ryan · Scott S. Emerson · Robert F. Kushner · Kirstine Brown-Frandsen · G. Kees Hovingh · Søren Hardt-Lindberg · Christoffer W. Tornøe
2 April 2026 at 08:00

Nature Medicine, Published online: 02 April 2026; doi:10.1038/s41591-026-04281-1

A prespecified analysis from the SELECT trial showed that semaglutide reduces major adverse cardiovascular events by 20% compared with placebo, particularly in patients at high risk of fibrosis, as indicated by the Fibrosis-4 index.
Received — 2 April 2026 ⏭ Nature Medicine

A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia

✇Nature Medicine
By: Lijun An · Alexa Pichet Binette · Ines Hristovska · Gabriele Vilkaite · Yu Xiao · Romina Zendehdel · Zijian Dong · Bart Smets · Rowan Saloner · Shinya Tasaki · Ying Xu · Varsha Krish · Farhad Imam · Shorena Janelidze · Danielle van Westen · Erik Stomrud · Christopher D. Whelan · Sebastian Palmqvist · Rik Ossenkoppele · Niklas Mattsson-Carlgren · Oskar Hansson · Jacob W. Vogel
31 March 2026 at 08:00

Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04303-y

ProtAIDe-Dx is a deep joint-learning model that uses plasma proteomics to provide simultaneous probabilistic diagnoses across six conditions associated with aging.

Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial

✇Nature Medicine
By: Princess U. Ogbogu · Florence Roufosse · Praveen Akuthota · Piotr Kuna · Matthieu Groh · Andreas Reiter · Akira Yokota · Salman H. Siddiqui · Pim G. N. J. Mutsaers · Bing Li · Paneez Khoury · Lila M. Bahadori · Artur Bednarczyk · Gerben Bouma · Laura G. Brooks · Jorge Ferreira · Hanna Grindebacke · Calvin N. Ho · Priya Jain · Rebecca L. Palmer · Maria L. Jison · Amy D. Klion
31 March 2026 at 08:00

Nature Medicine, Published online: 31 March 2026; doi:10.1038/s41591-026-04315-8

Benralizumab (an anti-IL-5 receptor α antibody), compared to placebo, significantly reduced the risk of first flare in patients with hypereosinophilic syndrome.
Received — 26 March 2026 ⏭ Nature Medicine

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study

✇Nature Medicine
By: Ning An · Di Wang · Peiling Zhang · Jishuai Zhang · Philippe Parone · Jianlin Hu · Yuhan Bao · Li Xu · Haitao Ruan · Ying Wan · Xinyu Wen · Yang Gao · Chunrui Li
25 March 2026 at 08:00

Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04244-6

In a phase 1 trial, the in vivo generation of anti-BCMA CAR-T cells by lentiviral delivery was feasible and did not lead to dose-limiting toxicities in five patients with relapsed or refractory multiple myeloma.

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

✇Nature Medicine
By: Wungki Park · Catherine A. O’Connor · Joanne F. Chou · Marc Hilmi · Zeynep Tarcan · Carly Schwartz · Mary Larsen · Ramzi Homsi · Karthigayini Sivaprakasam · Shigeaki Umeda · Maria A. Perry · Anna M. Varghese · Kenneth H. Yu · Fiyinfolu Balogun · Alice Zervoudakis · Seth S. Katz · Tae-Hyung Kim · Ken Zhao · Allison L. Richards · Nicolas Lecomte · Daniel Martin Muldoon · Elias Karnoub · Walid Chatila · Jessica Yang · Imane El-Dika · Devika Rao · Smita Joshi · Michael B. Foote · Ryan Sugarman · James J. Harding · Andrew S. Epstein · David Kelsen · Sree Chalassani · Fergus Keane · Joshua D. Schoenfeld · Anupriya Singhal · Erin Diguglielmo · Chaitanya Bandlamudi · Junmin Song · Hulya Sahin Ozkan · Junguei Hong · Haochen Zhang · Agustin III Cardenas · Maria Lao · Jerry Melchor · Ronak Shah · Wenfei Kang · Francesca Mazzoni · Kevin Soares · Mark TA Donoghue · Ernesto Santos · Vineet Rolston · Marsha Reyngold · Alice Chia-chi Wei · Murray Tipping · Olca Basturk · Michael Berger · Richard Kihn Do · Mark Schattner · William R. Jarnagin · Nadeem Riaz · Vinod Balachandran · Dana
25 March 2026 at 08:00

Nature Medicine, Published online: 25 March 2026; doi:10.1038/s41591-026-04299-5

Results of the phase 2 POLAR trial show that biomarker-guided treatment in patients with metastatic pancreatic cancer based on homologous repair deficiency leads to encouraging clinical response rates in immune cell-infiltrated tumors.

<i>LRRK2</i>-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial

✇Nature Medicine
By: Omar S. Mabrouk · Ben Tichler · H. Moore Arnold · Eva C. Thoma · Sara M. Alexanian · Jingxian Chen · Tzu-Ying Liu · Beth Hirschhorn · Roy Llorens Arenas · John W. Annand · Unnati Kapadnis · Alan A. Shomo · Kelly E. Glajch · Kyle Ferber · Yuka Moroishi · Julie Czerkowicz · Jennifer Inra · Ronald B. Postuma · Tanya Gurevich · Pablo Mir · Huw R. Morris · Jason Aldred · Matthew A. Brodsky · Aaron Ellenbogen · Danielle Larson · Christopher M. Tolleson · Andrew Siderowf · Charalampos Tzoulis · Ernest Balaguer · Maria J. Marti · Hien T. Zhao · Holly B. Kordasiewicz · Roger Lane · Warren D. Hirst · Stephanie Fradette · Danielle L. Graham
24 March 2026 at 08:00

Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04262-4

The first-in-human clinical trial of the LRRK2-targeting antisense oligonucleotide BIIB094 in Parkinson’s disease demonstrates that the treatment is well tolerated and produces dose-dependent reductions in cerebrospinal fluid levels of LRRK2 and phosphorylated Rab10, indicating successful target engagement.

AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial

✇Nature Medicine
By: Nick Woznitza · Lesley Smith · Janette Rawlinson · Iain Au-Yong · Bindu George · Madava G. Djearaman · Arjun Nair · Richard W. Lee · Neal Navani · Siyabonga Ndwandwe · Caroline S. Clarke · Andrew Creeden · Josh Newsome · Indrajeet Das · Sylvia Abaokporo · Richard Tucker · James Hathorn · David R. Baldwin
24 March 2026 at 08:00

Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04253-5

In a large UK-based primary care randomized trial, immediate artificial intelligence (AI)-driven prioritization of chest X-rays did not significantly shorten time to computed tomography or lung cancer diagnosis versus standard workflow, suggesting that AI-based prioritization alone is unlikely to accelerate the lung cancer diagnostic pathway.
Received — 17 March 2026 ⏭ Nature Medicine

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

✇Nature Medicine
By: Kohei Shitara · Hirokazu Shoji · Nicola Fazio · Sara Lonardi · Keun-Wook Lee · Li-Yuan Bai · Kensei Yamaguchi · Jean-Philippe Metges · Gianluca Masi · Denis Smith · Tae-Yong Kim · Maria Matsangou · Archita Shrivastava · Miaomai Zhou · Jason Hill · Abraham Guerrero · Xuewei Wang · Aziz Zaanan · Samuel J. Klempner
16 March 2026 at 08:00

Nature Medicine, Published online: 16 March 2026; doi:10.1038/s41591-026-04306-9

In cohort 4 of the ILUSTRO trial, combination of anti-CLDN18.2 zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive, HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma led to encouraging clinical efficacy, supporting the testing of this combination in a phase 3 trial.
Received — 14 March 2026 ⏭ Nature Medicine

A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial

✇Nature Medicine
By: Aurélie Ploquin · Rosemarie D. Mason · LaSonji A. Holman · Myra Happe · Alicia T. Widge · Laura Novik · Ana M. Ortega-Villa · Galina V. Yamshchikov · Ingelise J. Gordon · Abidemi Ola · Anita Arthur · Pamela J. M. Costner · Floreliz Mendoza · Jamie Saunders · Xioalin Wang · William R. Whalen · Joanna Utoh · Jennifer Cunningham · Lorin N. Loftus · Ashley Heimann · Katia Korzeniwsky · Shayne F. Andrew · Evan Lamb · Shruthi Shyam Sunder · Amelia Thompson · Mary McDonald · Kathryn E. Foulds · Nancy J. Sullivan · Jessica Bahorich · Emily E. Coates · Rebecca J. Loomis · Barney S. Graham · Karin Bok · Sunny Himansu · Brett Leav · Walla Dempsey · John H. Beigel · Mario Roederer · Lesia K. Dropulic · Maxwell Norris · Preeti Apte · Renunda Dyer · LaShawn Requilman · Justine Jones · Larisa Strom · Tatiana Beresnev · Maryam Keshtkar-Jahromi · Caitlyn Dulan · Li Ou · I-Ting Teng · Tongqing Zhou
12 March 2026 at 08:00

Nature Medicine, Published online: 12 March 2026; doi:10.1038/s41591-026-04265-1

In this phase 1, open-label dose-escalation study in healthy adults found that the mRNA vaccine (mRNA-1215), encoding the Nipah virus Malaysian strain chimeric pre-fusion F protein linked to glycoprotein G, was safe and induced elevated immune responses at 1 year of follow-up, indicating that this is a promising vaccine candidate for further development.

A cognitive layer architecture to support large-language model performance in psychotherapy interactions

✇Nature Medicine
By: Max Rollwage · Jessica McFadyen · Keno Juchems · Annamaria Balogh · Sashank Pisupati · Margareta-Theodora Mircea · Tobias U. Hauser · George Prichard · Ross Harper
12 March 2026 at 08:00

Nature Medicine, Published online: 12 March 2026; doi:10.1038/s41591-026-04278-w

A real-world study showed that introducing a cognitive layer architecture to support specialized psychotherapeutic reasoning capabilities in general-purpose chatbots improved depression and anxiety symptoms compared to chatbots or therapists alone.

A clinical environment simulator for dynamic AI evaluation

✇Nature Medicine
By: Luyang Luo · Sung Eun Kim · Xiaoman Zhang · Julius M. Kernbach · Roshan Kenia · Julian N. Acosta · Larry A. Nathanson · Adrian D. Haimovich · Adam Rodman · Ethan Goh · Jonathan H. Chen · Nigam H. Shah · David A. Kim · James Zou · Faisal Mahmood · Jakob Nikolas Kather · Matthew Lungren · Vivek Natarajan · Eric J. Topol · Pranav Rajpurkar
12 March 2026 at 08:00

Nature Medicine, Published online: 12 March 2026; doi:10.1038/s41591-026-04252-6

The authors propose a framework for clinical AI evaluation within simulated digital hospital environments that capture the evolving constraints, and cascading effects, of clinical decisions.

Author Correction: Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study

✇Nature Medicine
By: Jiyeon Oh · Soeun Kim · Yesol Yim · Min Seo Kim · Jae Il Shin · Ahmed A. J. Jabbar · Hasan Aalruz · Mohammadreza Abbasian · Abdallah H. A. Abd Al Magied · Samar Abd ElHafeez · Atef Abdelkader · Mawada Hassan Abdelmagied · Parsa Abdi · Mohammad-Amin Abdollahifar · Deldar Morad Abdulah · Auwal Abdullahi · Nigusie Abebaw · Roberto Ariel Abeldaño Zuñiga · Richard Gyan Aboagye · Hassan Abolhassani · Mohamed Abouzid · Lucas Guimarães Abreu · Dariush Abtahi · Rana Kamal Abu Farha · Ibrahim Jatau Abubakar · Eman Abu-Gharbieh · Hana J. Abukhadijah · Salahdein Aburuz · Ahmed Abu-Zaid · Juan Manuel Acuna · Mesafint Molla Adane · Isaac Yeboah Addo · Oyelola A. Adegboye · Victor Adekanmbi · Charles Oluwaseun Adetunji · Temitayo Esther Adeyeoluwa · Rishan Adha · Kishor Adhikari · Ripon Kumar Adhikary · Qorinah Estiningtyas Sakilah Adnani · Aanuoluwapo Adeyimika Afolabi · Rotimi Felix Afolabi · Fatemeh Afrashteh · Arya Afrooghe · Anurag Agrawal · Williams Agyemang-Duah · Aqeel Ahmad · Muayyad M. Ahmad · Sajjad Ahmad · Shahzaib Ahmad · Ali Ahmadi · Ayman Ahmed · Haroon Ah
11 March 2026 at 08:00

Nature Medicine, Published online: 11 March 2026; doi:10.1038/s41591-026-04288-8

Author Correction: Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study

Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis

✇Nature Medicine
By: Stephan A. Kaeser · Stephanie A. Schultz · Anna Hofmann · Lisa M. Häsler · Ying Xu · Marius Lambert · Ulrike Obermüller · Kathrin Brockmann · Johan Bijzet · Hans Nienhuis · Mario Nuvolone · Laura Obici · Giovanni Palladini · Ute Hegenbart · Stefan O. Schönland · Mathias Jucker
11 March 2026 at 08:00

Nature Medicine, Published online: 11 March 2026; doi:10.1038/s41591-026-04272-2

Elevated serum levels of phosphorylated tau are not specific to Alzheimer’s disease and may also serve as a diagnostic tool for the most common types of systemic amyloidosis, with potential utility in distinguishing amyloidosis-related polyneuropathy from polyneuropathy of other etiologies.
❌